How much does a box of Atrasentan cost in 2025? Is there any price reduction?

Atrasentan (Atrasentan), trade name Vanrafia, is a selective ETA type endothelin receptor antagonist developed by Novartis (Novartis). The drug received accelerated approval from the U.S. FDA at the beginning of 2025 for the treatment of primary IgAnephropathy (IgAN) in adult patients, as a supplement to traditionalRAAS suppressive therapy. Due to its positioning in the field of rare kidney diseases, atrasentan has become one of the high-value targeted drugs that the industry is paying attention to.

From a price point of view, the official price of atrasentan is relatively high. According to data from the public drug price platform, a box of medicine with specifications of 0.75mg*30 tablets costs approximately 14,267 US dollars, which is equivalent to more than 10 yuan in RMB. The annual medication cost is as high as approximately 162,000 US dollars (approximately 110 yuan), making it one of the more expensive new drugs in the current IgAN field. Since the drug is still an original drug, it has not yet faced competition from generic drugs, and its price has not shown any obvious signs of reduction.

As to whether there is a price reduction trend, as of mid-2025, there is no official news that atrasentan has seen a price reduction globally. At present, it has not been included in the medical insurance system of most countries, nor has it entered the Chinese market. Although some patients can obtain certain financial support in the United States through assistance projects, in overseas markets, especially self-pay patients, the burden is still high, and drug prices are still high.

Looking forward, if more clinical data supports its long-term efficacy and safety, and other similar drugs are launched one after another, the price of atrasentan may face pressure. In addition, once it applies for listing in more countries and negotiates with medical insurance, price reductions will be possible. At this stage, the drug is still in high price and limited supply. It is recommended that patients evaluate treatment plans under the guidance of doctors and obtain drug information and price support through formal channels.

Reference materials:https://www.drugs.com/